Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Theliatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.59 |
| ▸ | GAK | O14976 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | FBP1 | P09467 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theliatinib SCHEMBL247509 | 1.00 | EGFR (0.62) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514684 | 0.95 | EGFR (0.64) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514680 | 0.90 | EGFR (0.66) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514745 | 0.87 | EGFR (0.63) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514677 | 0.87 | EGFR (0.68) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1766079 | 0.86 | EGFR (0.73) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514686 | 0.85 | EGFR (0.66) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514674 | 0.85 | EGFR (0.65) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514678 | 0.84 | EGFR (0.65) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514688 | 0.84 | EGFR (0.67) | EGFRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250275978-A1 | USE OF ONVANSERTIB AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY, INC. | 2025-09-04 | — | — | US | claimed |
| CN-120091813-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-4531846-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2025049814-A2 | RIBONUCLEOTIDE REDUCTASE (RNR) COMPOSITIONS AND METHODS OF USE | BOUNDLESS BIO, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2024254465-A2 | METHODS FOR PROMOTING EXPANSION OF HUMAN CD34+ CELLS IN VIVO AND FOR PROMOTING NEURAL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024196923-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | BOUNDLESS BIO, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| EP-4284519-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | The Regents of the University of California (US) | 2023-12-06 | — | — | EP | claimed |
| EP-4281560-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | The Regents of the University of California (US) | 2023-11-29 | — | — | EP | claimed |
| CN-116829142-A | Methods for treating and ameliorating cancer | 加利福尼亚大学董事会 | 2023-09-29 | — | — | CN | claimed |
| US-11723891-B2 | Drug combinations for use in the treatment of RAS-mutant cancer | UMC UTRECHT HOLDING B.V. (NL) | 2023-08-15 | — | — | US | claimed |
| WO-2023051606-A1 | MEDICAL USE OF SHP2 INHIBITOR IN COMBINATION WITH EGFR-TKI IN TREATMENT AND PREVENTION OF TUMOR DISEASES | 上海翰森生物医药科技有限公司 | 2023-04-06 | — | — | WO | claimed |
| US-11612601-B1 | Targeting epidermal growth factor to treat vascular calcification | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-03-28 | — | — | US | claimed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2022165398-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | WO | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | EGFR 2435/4885HDAC3 2094/4885HDAC4 1940/4885 |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | PLK1, BRAF, KRAS | EGFR 6/4885HDAC3 2740/4885HDAC4 1696/4885 |
| US-20250275978-A1 | USE OF ONVANSERTIB AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | KRAS, PLK1, NRAS | EGFR 10/4885HDAC3 3012/4885HDAC4 1478/4885 |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | EGFR 24/4885HDAC3 2152/4885HDAC4 1288/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885HDAC3 2519/4885HDAC4 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.